Keytruda Disappoints in Phase III SCC Trial; Merck Halts Study
Merck is discontinuing the Phase 3 KEYNOTE-630 trial evaluating (pembrolizumab, Keytruda) for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the recommendation of an independent Data Monitoring Committee (DMC). The DMC stated that the study be stopped as the risk/benefit profile did not […]